UNSPSC 51162352: Diphenhydramine/guaifenesin/menthol/sodium citrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162352 Diphenhydramine/guaifenesin/menthol/sodium citrate is a Commodity code that covers specific OTC cough and cold formulations state and local governments procure for public health programs, emergency response, and health department inventories. Recent solicitations show state and local buyers purchasing this product alongside related pharmaceutical inventory — naloxone, generic multi-source drugs, and complementary OTC items — rather than as a standalone line item. The code sees activity from county health departments and state-level cooperative purchasing alliances coordinating multi-jurisdiction pharmaceutical procurement.

Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking naloxone and drug deactivation systems for community health initiatives with quarterly deliveries, and the Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. MMCAP's procurement emphasizes price competitiveness (weighted at 75 percent in evaluation), compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and distribution through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson. Recent activity concentrates in the upper Midwest and Southeast, with MMCAP's multi-state cooperative model suggesting broader regional reach across participating jurisdictions.